Scientific Reports · Nov 20, 2026
Association of miR-503 derived from senescent endothelial cell ‑derived extracellular vesicles with MST1 m6A modification and mitochondrial dysfunction of cardiomyocytes in heart failure
By Deng B, Peng Z, Zhang X et al.
This study investigates the role of miR-503 in mitochondrial dysfunction related to heart failure (HF), specifically how it is carried by extracellular vesicles from senescent endothelial cells (EVssenescent), affecting m6A modification in cardiomyocytes. A rat model of endothelial cell senescence was used to produce EVssenescent. HF was induced in rats using doxorubicin (DOX) and treated with EVssenescent, EVsmiR-503 antagomir, and DAA. Cardiac function, tissue fibrosis, and NT-proBNP levels were assessed using echocardiography, histological staining, and ELISA, respectively. Mitochondrial markers TOM20 and LC3B were analyzed. DOX-treated H9C2 cells were developed as a cell model, with mitophagy, mitochondrial function, cell viability, and the levels of marker proteins and miR-503 measured. Total m6A was quantified, and m6A methylation sites on MST1 mRNA were predicted and subsequently validated. EVssenescent showed high miR-503, inhibiting mitophagy and promoting mitochondrial dysfunction, thereby worsening HF in rats. These effects were partially reversed by miR-503 antagomir. EVssenescent miR-503 repressed mitophagy and increased mitochondrial dysfunction in DOX-treated cardiomyocytes. Mitophagy activation reduced the adverse effects of EVssenescent. An m6A methylation site on MST1 was identified. miR-503 delivered by EVssenescent was correlated with MST1/m6A modification and mitochondrial dysfunction. EVssenescent miR-503 to modulate MST1 expression in an m6A modification-dependent manner, thereby suppressing mitophagy, aggravating mitochondrial dysfunction, and exacerbating HF in rats.